Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco

BIOCQ

PR Newswire

SAN DIEGO, Aug. 28, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at the 6th Annual Liolios Gateway Conference on Wednesday, September 6 th, 2017, at 8:30 a.m. Pacific time (11:30 a.m. Eastern time).  The conference is being held at the Four Seasons Hotel in San Francisco.

Biocept Logo (PRNewsFoto/Biocept, Inc.)

A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com.  A replay of the presentations will be available for 90 days.  The 6th Annual Gateway Conference will feature more than 100 companies from growth industries.  For more information, visit www.gateway-conference.com.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.  The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).  With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-6th-annual-gateway-conference-on-september-6-2017-in-san-francisco-300509765.html

SOURCE Biocept, Inc.